Impact of Azithromycin Studied in Acute Exacerbation of COPD

FRIDAY, May 3, 2019 -- Three months of azithromycin did not significantly reduce treatment failure (TF) among patients hospitalized for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), according to a study published online...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

Condition:   Pulmonary Disease, Chronic Obstructive Interventions:   Drug: Placebo;   Biological: Mepolizumab Sponsors:   GlaxoSmithKline;   PPD Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionsThe findings suggest that addressing self-management related domains, in addition to self-efficacy, dyspnea, and comorbidities, may be of importance for enhancement of HRQoL in persons with COPD.
Source: Quality of Life Research - Category: Health Management Source Type: research
This study was designed to investigate whether angiogenesis factors could serve as noninvasive markers for the diagnosis of PH in the COPD patient and which could serve as therapeutic targets.
Source: Journal of Vascular Surgery - Category: Surgery Authors: Source Type: research
Pulmonary hypertension related to chronic lung disease, mainly represented by COPD and idiopathic pulmonary fibrosis, is associated with a worse outcome when compared with patients only affected by parenchymal lung disease. At present, no therapies are available to reverse or slow down the pathological process of this condition and most of the clinical trials conducted to date have had no clinically significant impact. Nevertheless, the importance of chronic lung diseases is always more widely recognised and, along with its increasing incidence, associated pulmonary hypertension is also expected to be growing in frequency ...
Source: European Respiratory Review - Category: Respiratory Medicine Authors: Tags: Pulmonary vascular disease Reviews Source Type: research
ConclusionAccording to this study increasing the NO2 concentration has a direct and a significant effect on chronic obstructive pulmonary diseases. Electrical heating, alternative fuels solar and cooking are important factors in decreasing the concentration of NO2.
Source: Clinical Epidemiology and Global Health - Category: Epidemiology Source Type: research
Source: International Journal of Tuberculosis and Lung Disease - Category: Respiratory Medicine Authors: Tags: ORIGINAL ARTICLES Source Type: research
ConclusionsThe results of this meta-analysis show that LABA/LAMA combinations are consistently more effective than ICS/LABA FDCs for most of the evaluated outcomes. However, differences have also been observed between FDCs belonging to the same class. Across the investigated LABA/LAMA FDCs, glycopyrronium/indacaterol revealed a consistent and robust efficacy profile.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research
New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Source Type: research
New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Source Type: research
AbstractIntroductionRisk of osteoporosis known to increase in COPD, but is usually overlooked, especially in male patients.ObjectivesThe present study compares the bone mineral density (BMD) measurements of male COPD patients with emphysema and the chronic bronchitis phenotype, and evaluates the association between density of emphysema and osteoporosis.Methods94 patients with COPD, and with emphysema and the chronic bronchitis phenotype were included in the prospective study. A high resolution computed tomography (HRCT) was used for the diagnosis of emphysema, dual X ‐ray absorptiometry was used to measure the BMD of the...
Source: The Clinical Respiratory Journal - Category: Respiratory Medicine Authors: Tags: ORIGINAL ARTICLE Source Type: research
More News: Azithromycin | Chronic Obstructive Pulmonary | Pharmaceuticals | Study | Zithromax